ArticleTransplant international : official journal of the European Society for Organ Transplantation2023
The Relevance of Advanced Therapy Medicinal Products in the Field of Transplantation and the Need for Academic Research Access: Overcoming Bottlenecks and Claiming a New Time.
Article in Transplant international : official journal of the European Society for Organ Transplantation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Designs of the clinical trials aiming at evaluating cell and gene therapy products: A critical appraisal from a literature review.Molecular therapy. Advances · 2026Review
- Developing European policy on xenotransplantation: instructive findings from the first representative UK sample survey on attitudes and views on animal to human transplants.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Current challenges and future directions of ATMPs in regenerative medicine.Regenerative therapy · 2025Review
- Extracorporeal Photopheresis: Does It Have a Potential Place Among Cell-based Therapies?Transplantation direct · 2025Article
- 3D Printing for Neural Repair: Bridging the Gap in Regenerative Medicine.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Challenges in the clinical translation of stromal vascular fraction therapy in regenerative medicine.World journal of stem cells · 2025Review
- The Last Mile in Beta-Cell Replacement Therapy for Type 1 Diabetes: Time to Grow Up.Transplant international : official journal of the European Society for Organ Transplantation · 2025Review
- Allogeneic Islet Transplantation: Chronicle of a Death Foretold?Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- The bio-artificial pancreas to treat type 1 diabetes: Perspectives from healthcare professionals in the Netherlands.Journal of clinical & translational endocrinology · 2024Article
- Mesenchymal Stromal Cell-Based Products: Challenges and Clinical Therapeutic Options.International journal of molecular sciences · 2024Review
- ESOT Roadmap for Advanced Therapy Medicinal Products in Transplantation: Navigating Regulatory Challenges to Enhance Access and Care.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Drug outcomes research and policies - trends and challenges.Frontiers in pharmacology · 2024Article
- Cautious Optimism Warranted for Stem Cell-Derived Islet Transplantation in Type 2 Diabetes.Transplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Organizational aspects of tissue engineering clinical translation: insights from a qualitative case study.Translational medicine communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The field of transplantation has witnessed the emergence of Advanced Therapy Medicinal Products (ATMPs) as highly promising solutions to address the challenges associated with organ and tissue transplantation. ATMPs encompass gene therapy, cell therapy, and tissue-engineered products, hold immense potential for breakthroughs in overcoming the obstacles of rejection and the limited availability of donor organs. However, the development and academic research access to ATMPs face significant bottlenecks that hinder progress. This opinion paper emphasizes the importance of addressing bottlenecks in the development and academic research access to ATMPs by implementing several key strategies. These include the establishment of streamlined regulatory processes, securing increased funding for ATMP research, fostering collaborations and partnerships, setting up centralized ATMP facilities, and actively engaging with patient groups. Advocacy at the policy level is essential to provide support for the development and accessibility of ATMPs, thereby driving advancements in transplantation and enhancing patient outcomes. By adopting these strategies, the field of transplantation can pave the way for the introduction of innovative and efficacious ATMP therapies, while simultaneously fostering a nurturing environment for academic research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.